<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01074125</url>
  </required_header>
  <id_info>
    <org_study_id>KRX-0502-305</org_study_id>
    <nct_id>NCT01074125</nct_id>
  </id_info>
  <brief_title>A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease</brief_title>
  <official_title>A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) Following a Two-Week Washout Period</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Keryx Biopharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Collaborative Study Group (CSG)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Keryx Biopharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a research study for people with high blood phosphorus levels who are on dialysis.
      This medical condition can cause weakening of the bones and damage other organs. This can
      lead to many health problems, and sometimes death. Phosphorus is in much of the food we eat,
      and is helpful to us in small amounts. Patients with kidney failure have trouble getting rid
      of the phosphorus eaten in food. Dialysis can help remove some of the phosphorus, but often
      patients must take a phosphate binder like PhosLo®, Renagel®, or Renvela® to bring the blood
      phosphorus levels back to normal. The purpose of this study is to see if KRX-0502 (ferric
      citrate) is safe and effective as a phosphate binder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There will be a screening visit about 4 weeks receiving study drug. Upon qualifying for the
      study after the screening visit, patients will then be asked to stop taking their current
      phosphate binder for about 2 weeks. Then, if patients continue to qualify for the study, they
      will be entered in the study that lasts about 28 days. Study visits will happen every week
      during the patient's usual dialysis appointments. There will be a total of up to 9 visits for
      this study, and total participation time could last up to 8 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Serum Phosphorus From Baseline to End of Treatment</measure>
    <time_frame>Baseline and day 28</time_frame>
    <description>Mean change from baseline was calculated separately for each treatment arm (LOCF)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pairwise Comparison of the Mean Change in Serum Phosphorus From Baseline to the End of Treatment</measure>
    <time_frame>Baseline and day 28</time_frame>
    <description>Mean change from baseline was calculated separately for each treatment arm. Only subjects that have both baseline and end of treatment serum phosphorus scores were analyzed for this outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patient With a Serum Phosphorus ≤5.5 mg/dL at the End of Treatment</measure>
    <time_frame>Baseline and day 28</time_frame>
    <description>proportion was calculated separately for each treatment arm</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">154</enrollment>
  <condition>Hyperphosphatemia</condition>
  <condition>End-Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>1 g/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 g/day KRX-0502 (ferric citrate)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6 g/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 g/day KRX-0502 (ferric citrate)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>8 g/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 g/day KRX-0502 (ferric citrate)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ferric citrate</intervention_name>
    <description>1, 6, or 8 g/day taken within 1 hour of meals or snacks daily for 28 days</description>
    <arm_group_label>1 g/day</arm_group_label>
    <arm_group_label>6 g/day</arm_group_label>
    <arm_group_label>8 g/day</arm_group_label>
    <other_name>KRX-0502</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or non-pregnant, non-lactating females

          -  Age &gt; 18 years

          -  On thrice weekly hemodialysis or peritoneal dialysis for at least the previous three
             months prior to Screening Visit (Visit 0)

          -  Serum phosphorus levels ≥ 3.5 mg/dL and &lt; 8.0 mg/dL at Screening Visit (Visit 0)

          -  Serum phosphorus levels &gt; 6.0 mg/dL during the washout period (Visits 2 or 3)

          -  Taking 3 to 15 tablets/capsules per day of 667mg calcium acetate or 800 mg sevelamer
             (hydrochloride or carbonate), or any combination of these agents as reported by the
             patient at Screening Visit (Visit 0)

          -  Serum ferritin &lt;1000micrograms/L and Transferrin Saturation (TSAT) &lt;50% at the
             Screening Visit (Visit 0)

          -  Willingness to be discontinued from current phosphate binder(s) and initiated on
             KRX-0502 (ferric citrate)

          -  Willing and able to give informed consent

          -  Willing and able to stay on a constant dose of Vitamin D (or its analogs) and Sensipar
             (cinacalcet) for the treatment period, if applicable.

        Exclusion Criteria:

          -  Parathyroidectomy within six months prior to Screening Visit (Visit 0)

          -  Actively symptomatic gastrointestinal bleeding or inflammatory bowel disease

          -  Serum phosphorus levels &gt;10.0 mg/dL documented in all of the three monthly
             laboratories (done routinely in the dialysis unit) in the three months prior to the
             Screening Visit (Visit 0)

          -  History of multiple drug allergies or intolerances

          -  History of malignancy in the last five years (treated cervical or non-melanomatous
             skin cancer may be permitted if approved by CCC)

          -  Previous intolerance to oral ferric citrate

          -  Absolute requirement for oral iron therapy

          -  Absolute requirement for Vitamin C (multivitamins [Nephrocaps, Renaphro, etc.]
             allowed)

          -  Absolute requirement for calcium-, magnesium-, or aluminum-containing drugs with meals

          -  Psychiatric disorder that interferes with the patient's ability to comply with the
             study protocol

          -  Inability to tolerate oral drug intake

          -  Planned surgery or hospitalization during the trial (scheduled outpatient access
             surgery allowed)

          -  Any other medical condition that renders the patient unable to or unlikely to complete
             the trial or that would interfere with optimal participation in the trial or produce
             significant risk to the patient

          -  Receipt of any investigational drug within 30 days of Screening Visit (Visit 0)

          -  Inability to cooperate with study personnel or history of noncompliance

          -  Unsuitable for this trial per Principal Investigator's clinical judgment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julia B Lewis, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Collaborative Study Group (CSG)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Western Nephrology</name>
      <address>
        <city>Westminster</city>
        <state>Colorado</state>
        <zip>80031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pines Clinical Research, Inc.</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kidney Care Associates, LLC</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Circle Medical Management</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western New England Renal &amp; Transplant Associates</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brookdale Physician's Dialysis Associates</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DCI</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinical Foundation Fresenius East (Fairhill)</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Cramblett Medical Clinic</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeast Renal Research Institute</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nephrology Associates, PC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meharry Medical College Clinical Research Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center Clinical Trials Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-1371</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kidney Associates</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Point Dialysis</name>
      <address>
        <city>West Allis</city>
        <state>Wisconsin</state>
        <zip>53214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RCMI- Clinical Research Center Medical Sciences Campus University of Puerto Rico</name>
      <address>
        <city>Rio Piedras</city>
        <zip>00936-5067</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2010</study_first_submitted>
  <study_first_submitted_qc>February 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2010</study_first_posted>
  <results_first_submitted>October 4, 2014</results_first_submitted>
  <results_first_submitted_qc>December 3, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 4, 2014</results_first_posted>
  <last_update_submitted>December 3, 2014</last_update_submitted>
  <last_update_submitted_qc>December 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hyperphosphatemia</keyword>
  <keyword>ESRD</keyword>
  <keyword>Dialysis</keyword>
  <keyword>End Stage Renal Disease</keyword>
  <keyword>Phosphorus</keyword>
  <keyword>Renal</keyword>
  <keyword>Kidney</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Hyperphosphatemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Ferric Compounds</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>3 patients were randomized, but withdrew before initiating study treatment</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>1 g/Day</title>
          <description>1 g/day KRX-0502 (ferric citrate) taken within 1 hour of meals or snacks daily for 28 days</description>
        </group>
        <group group_id="P2">
          <title>6 g/Day</title>
          <description>6 g/day KRX-0502 (ferric citrate) taken within 1 hour of meals or snacks daily for 28 days</description>
        </group>
        <group group_id="P3">
          <title>8 g/Day</title>
          <description>8 g/day KRX-0502 (ferric citrate) taken within 1 hour of meals or snacks daily for 28 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="52"/>
                <participants group_id="P3" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="47"/>
                <participants group_id="P3" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-treat</population>
      <group_list>
        <group group_id="B1">
          <title>1 g/Day</title>
          <description>1 g/day KRX-0502 (ferric citrate) taken within 1 hour of meals or snacks daily for 28 days</description>
        </group>
        <group group_id="B2">
          <title>6 g/Day</title>
          <description>6 g/day KRX-0502 (ferric citrate) taken within 1 hour of meals or snacks daily for 28 days</description>
        </group>
        <group group_id="B3">
          <title>8 g/Day</title>
          <description>8 g/day KRX-0502 (ferric citrate) taken within 1 hour of meals or snacks daily for 28 days</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="51"/>
            <count group_id="B3" value="45"/>
            <count group_id="B4" value="146"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Puerto Rico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Serum Phosphorus From Baseline to End of Treatment</title>
        <description>Mean change from baseline was calculated separately for each treatment arm (LOCF)</description>
        <time_frame>Baseline and day 28</time_frame>
        <population>Intent to Treat (ITT) Population</population>
        <group_list>
          <group group_id="O1">
            <title>1 g/Day</title>
            <description>1 g/day KRX-0502 (ferric citrate)
ferric citrate: 1, 6, or 8 g/day taken within 1 hour of meals or snacks daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>6 g/Day</title>
            <description>6 g/day KRX-0502 (ferric citrate)
ferric citrate: 1, 6, or 8 g/day taken within 1 hour of meals or snacks daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>8 g/Day</title>
            <description>8 g/day KRX-0502 (ferric citrate)
ferric citrate: 1, 6, or 8 g/day taken within 1 hour of meals or snacks daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Phosphorus From Baseline to End of Treatment</title>
          <description>Mean change from baseline was calculated separately for each treatment arm (LOCF)</description>
          <population>Intent to Treat (ITT) Population</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" spread="1.285"/>
                    <measurement group_id="O2" value="-1.86" spread="1.692"/>
                    <measurement group_id="O3" value="-2.13" spread="1.998"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>To assess dose ranging, the primary efficacy variable will be analyzed via a model with dose effect. Positive dose ranging confirmed if the null hypothesis of slope =0 was rejected at a significance level of 0.05</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Linear</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.3376</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pairwise Comparison of the Mean Change in Serum Phosphorus From Baseline to the End of Treatment</title>
        <description>Mean change from baseline was calculated separately for each treatment arm. Only subjects that have both baseline and end of treatment serum phosphorus scores were analyzed for this outcome.</description>
        <time_frame>Baseline and day 28</time_frame>
        <population>Intent-to-Treat, includes only subjects that had both baseline and end of study actual values</population>
        <group_list>
          <group group_id="O1">
            <title>1 g/Day</title>
            <description>1 g/day KRX-0502 (ferric citrate) taken within 1 hour of meals or snacks daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>6 g/Day</title>
            <description>6 g/day KRX-0502 (ferric citrate) taken within 1 hour of meals or snacks daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>8 g/Day</title>
            <description>8 g/day KRX-0502 (ferric citrate) taken within 1 hour of meals or snacks daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Pairwise Comparison of the Mean Change in Serum Phosphorus From Baseline to the End of Treatment</title>
          <description>Mean change from baseline was calculated separately for each treatment arm. Only subjects that have both baseline and end of treatment serum phosphorus scores were analyzed for this outcome.</description>
          <population>Intent-to-Treat, includes only subjects that had both baseline and end of study actual values</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="1.320"/>
                    <measurement group_id="O2" value="-1.94" spread="1.813"/>
                    <measurement group_id="O3" value="-2.21" spread="2.097"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patient With a Serum Phosphorus ≤5.5 mg/dL at the End of Treatment</title>
        <description>proportion was calculated separately for each treatment arm</description>
        <time_frame>Baseline and day 28</time_frame>
        <population>Intent-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>1 g/Day</title>
            <description>1 g/day KRX-0502 (ferric citrate)
ferric citrate: 1, 6, or 8 g/day taken within 1 hour of meals or snacks daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>6 g/Day</title>
            <description>6 g/day KRX-0502 (ferric citrate)
ferric citrate: 1, 6, or 8 g/day taken within 1 hour of meals or snacks daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>8 g/Day</title>
            <description>8 g/day KRX-0502 (ferric citrate)
ferric citrate: 1, 6, or 8 g/day taken within 1 hour of meals or snacks daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patient With a Serum Phosphorus ≤5.5 mg/dL at the End of Treatment</title>
          <description>proportion was calculated separately for each treatment arm</description>
          <population>Intent-to-Treat</population>
          <units>% of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0"/>
                    <measurement group_id="O2" value="51.0"/>
                    <measurement group_id="O3" value="57.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious Adverse Events (AEs) were recorded up to 30 days post therapy</time_frame>
      <group_list>
        <group group_id="E1">
          <title>1g/Day</title>
          <description>Participants received 1g tablet of KRX-0502 (ferric citrate) for 4 weeks</description>
        </group>
        <group group_id="E2">
          <title>6g/Day</title>
          <description>Participants received 6g tablet of KRX-0502 (ferric citrate) for 4 weeks</description>
        </group>
        <group group_id="E3">
          <title>8g/Day</title>
          <description>Participants received 8g tablet of KRX-0502 (ferric citrate) for 4 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Hypertensive heart disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Umbilical hernia, obstructive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Subcutaneous absess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arteriovenous fistula aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood glucose fluctuation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Pulmonary Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Pulmonary Odema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Renal transplant</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Hypertensive emergency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="51"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="52"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Faeces discoloured</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="51"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="52"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="52"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Information</name_or_title>
      <organization>Keryx Biopharmaceuticals Inc</organization>
      <phone>1-844-44-KERYX (1-844-445-3799</phone>
      <email>medicalinfo@keryx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

